Multiplicom Garners Extended CE Mark for BRCA Testing Kit

Sep

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care.

Oct

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

Menu

Multiplicom Garners Extended CE Mark for BRCA Testing Kit

To read the full story....

Breaking News

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Fulgent Inks $125M Equity Distribution Agreement With Piper Sandler

FDA Grants Emergency Use Authorization for Jiangsu Well Biotech Coronavirus Antibody Test

BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

What's Popular?

Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

Illumina to Acquire Grail for $8B in Cash and Stock

JP Morgan Downgrades Illumina to Neutral on Grail Deal

Sponsorships